Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrent Squamous Cell Lung Carcinoma 1

Interventions

durvalumab 3Immunoglobulin G 3Disulfides 3tremelimumab 2Nivolumab 2Ipilimumab 2Docetaxel 2CTLA-4 Antigen 22-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide 2telisotuzumab vedotin 1talazoparib 1rilotumumab 1palbociclib 1Erlotinib Hydrochloride 1AZD4547 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Recurrent Squamous Cell Lung Carcinoma × telisotuzumab vedotin × Clear all
NCT03574753 2021-10-18

Lung-MAP S1400K: c-MET Positive

SWOG Cancer Research Network

Phase 2 Completed
28 enrolled 18 charts

Recurrent Squamous Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡